Allogene Therapeutics, Inc.
cema-cel
large B-cell lymphoma
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for cema-cel in large B-cell lymphoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“At the protocol-defined data cutoff, triggered when the 24th patient enrolled in the ongoing study arms completed the Day 45 MRD assessment, 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity compared to 16.7% (2/12) in th”